±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼ : À¯Çüº°, Á¦Ç°º°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2032³â)
Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032
»óǰÄÚµå
:
1388188
¸®¼Ä¡»ç
:
Polaris Market Research
¹ßÇàÀÏ
:
2023³â 10¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 115 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
Polaris market researchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 29¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
±¸°°ÇÁ¶Áõ Á¦Ç°¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥, Áï ±¸°°ÇÁ¶Áõ Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ´Â ºñ¿ëÀÇ ÀϺΰ¡ º¸ÇèÀ̳ª ÀǷẸÇè¿¡¼ º¸ÀåµÇ±â ¶§¹®¿¡ ´õ ½±°í Àú·ÅÇÑ ºñ¿ëÀ¸·Î ÀÌ·¯ÇÑ Á¦Ç°À» ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. À̴ ȯÀÚµéÀÌ Ä¡·á¸¦ ¹Þµµ·Ï À¯µµÇÏ°í ±Ã±ØÀûÀ¸·Î ±¸°°ÇÁ¶Áõ °ü·Ã Á¦Ç° ¹× ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. ±¸°°ÇÁ¶ÁõÀº Á¾Á¾ ¼î±×·» ÁõÈıº, ´ç´¢º´, °íÇ÷¾Ð, ÆÄŲ½¼º´°ú °°Àº ±âÀúÁúȯÀÇ Áõ»óÀ̳ª ºÎÀÛ¿ëÀ¸·Î ³ªÅ¸³ª´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ ÀÇ·áÁø°ú ÀϹÝÀεéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº »ç·Ê°¡ Áø´Ü ¹× Ä¡·áµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº ÀÌ·¯ÇÑ ±âÀúÁúȯÀ» °¡Áø ȯÀÚÀÇ ±¸°°ÇÁ¶Áõ Áõ»óÀ» ÆÄ¾ÇÇϰí Ä¡·áÇÒ °¡´É¼ºÀÌ ³ô¾ÆÁö±â ¶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Colgate-Palmolive Company¿Í Sjogren Syndrome Foundation of America¿Í °°Àº ±â°ü¿¡¼ Á¦°øÇÏ´Â Åë°è´Â ¹Ì±¹ ³» ±¸°°ÇÁ¶Áõ ¹× °ü·Ã ÁúȯÀÇ À¯º´·üÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼öÄ¡´Â È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺°ú ´õ Å« °Ç° ¹®Á¦ÀÇ Áõ»óÀ¸·Î¼ ±¸°°ÇÁ¶ÁõÀ» ´Ù·ç´Â °ÍÀÇ Á߿伺À» °Á¶ÇÕ´Ï´Ù.
¼î±×·» ÁõÈıº Àç´ÜÀº ¼î±×·» ÁõÈıº¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í ±¸°°ÇÁ¶ÁõÀ» ¾Î°í ÀÖ´Â ¼î±×·» ÁõÈıº ȯÀÚµéÀ» µ½±â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ Àç´ÜÀº ¹Ì±¹°ú ij³ª´Ù¿¡¼ ÀÌ ÀÚ°¡¸é¿ªÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀ» Áö¿øÇϰí, 2017³â±îÁö ¼î±×·» ÁõÈıº Áø´Ü ±â°£À» 2.5³â À̳»·Î ´ÜÃàÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â '5-Year Breakthrough Goal'À» µµÀÔÇØ ÀÎ½Ä °³¼± ÇÁ·Î±×·¥À» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ¼î±×·» ÁõÈıºÀÇ Áø´Ü°ú Ä¡·á ¼Óµµ¸¦ ³ôÀ̰í, Á¾ÇÕÀûÀÎ Ä¡·á °èȹÀÇ ÀÏȯÀ¸·Î ±¸°°ÇÁ¶Áõ ¹®Á¦¸¦ ÇØ°áÇϰíÀÚ Çß½À´Ï´Ù.
¶ÇÇÑ, ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ½ºÅ¸Æ®¾÷ Àμö¿Í ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ ½ÇÇàÀÇ Á߿伺À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿À¶óÁ©(Orajel)Àº ¾ÆÀÌÅ©·Î½Ì(iCrossing)°ú ÇÔ²² Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ä·ÆäÀÎÀÇ ¸ñÀûÀº ±¸°°ÇÁ¶Áõ°ú °°Àº ¹®Á¦ ÇØ°áÀ» Æ÷ÇÔÇÑ ±¸° °ü¸®ÀÇ Á߿伺¿¡ ´ëÇØ ºÎ¸ð¸¦ ±³À°ÇÏ´Â °ÍÀ̾ú½À´Ï´Ù. ±¸° °Ç° ¹× ±¸°°ÇÁ¶Áõ°ú °°Àº Áõ»ó¿¡ ´ëÇØ ´ëÁßÀ» ±³À°ÇÔÀ¸·Î½á, ÀÌ·¯ÇÑ ³ë·ÂÀº ±¸°°ÇÁ¶Áõ°ú ±× Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
OTC ÀǾàǰ ºÎ¹®Àº ½±°Ô ±¸ÇÒ ¼ö ÀÖ°í, °¡°ÝÀÌ Àú·ÅÇϸç, À¯È¿À²ÀÌ ³ô±â ¶§¹®¿¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
Ä¡¾à ºÎ¹®Àº Çʼö Ÿ¾× ¼ººÐÀÎ Ä®½·°ú Àλ꿰À» ȸº¹½ÃÄÑ Å¸¾× ÀÚ±ØÁ¦¸¦ °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ´õ È¿À²ÀûÀ̱⠶§¹®¿¡ ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì Áö¿ªÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â ÁÖ·Î ±¸°°ÇÁ¶ÁõÀÇ ÆóÇØ¿¡ ´ëÇÑ È¯ÀÚµéÀÇ Àνİú ¹ß´ÞµÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇÑ È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ±âÀÎÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¾÷°è ÇöȲ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- ±¸° °Ç° »óÅ À¯º´·ü Áõ°¡
- ¿ÏÈ Äɾî¿Í ÁöÁö¿ä¹ý ¼ö¿ä Áõ°¡
- ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
- ÀϺΠ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ÀÇ ºÎÀÛ¿ë
- PESTLE ºÐ¼®
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ¾÷°è µ¿Çâ
- ¹ë·ùüÀÎ ºÐ¼®
- COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®
Á¦5Àå ¼¼°èÀÇ ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- Ÿ¾× ÀÚ±ØÁ¦
- Ÿ¾× ´ëüǰ
- Ä¡¾àÁ¦
Á¦6Àå ¼¼°èÀÇ ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, À¯Çüº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- OTC ÀǾàǰ
- 󹿾à
Á¦7Àå ¼¼°èÀÇ ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ºÏ¹Ì
- ºÏ¹Ì : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, À¯Çüº°, 2019-2032³â
- ºÏ¹Ì : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¹Ì±¹
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ij³ª´Ù
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - À¯·´
- À¯·´ : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¾·ùº°, 2019-2032³â
- À¯·´ : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¿µ±¹
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ÇÁ¶û½º
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - µ¶ÀÏ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ÀÌÅ»¸®¾Æ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ½ºÆäÀÎ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ³×µ¨¶õµå
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ·¯½Ã¾Æ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¾·ùº°, 2019-2032³â
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - Áß±¹
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - Àεµ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¸»·¹À̽þÆ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ÀϺ»
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - Àεµ³×½Ã¾Æ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - Çѱ¹
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¾·ùº°, 2019-2032³â
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - UAE
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - À̽º¶ó¿¤
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, À¯Çüº°, 2019-2032³â
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¸ß½ÃÄÚ
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ºê¶óÁú
- ±¸°°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª
Á¦8Àå °æÀï »óȲ
- È®Àå°ú Àμö ºÐ¼®
- Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦9Àå ±â¾÷ °³¿ä
- Acacia Pharma
- Church & Dwight Co., Inc.
- Colgate-Palmolive Company
- GlaxoSmithKline plc
- Hikma Pharmaceuticals PLC
- Lupin Pharmaceuticals, Inc.
- OraCoat
- Parnell Pharmaceuticals, Inc.
- Pendopharm
- Pfizer, Inc.
- Sun Pharmaceuticals Industries Ltd.
ksm
¿µ¹® ¸ñÂ÷
The global xerostomia therapeutics market size is expected to reach USD 2.94 billion by 2032, according to a new study by Polaris market research. The report "Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Favorable reimbursement policies for xerostomia products. This means that individuals who require treatment for xerostomia can access these products more easily and at reduced costs, as a portion of their expenses is covered by insurance or healthcare plans. This encourages patients to seek treatment, ultimately driving the demand for xerostomia-related products and medications. Xerostomia is often a symptom or side effect of underlying conditions such as Sjogren's syndrome, diabetes, hypertension, and Parkinson's disease.
As awareness of these diseases increases among both healthcare professionals and the general population, more cases are being diagnosed and treated. This, in turn, has a positive impact on the demand for xerostomia treatments, as healthcare providers are more likely to identify and address dry mouth symptoms in patients with these underlying conditions. For instance, statistics provided by organizations like Colgate-Palmolive Company and the Sjogren Syndrome Foundation of America highlight the prevalence of xerostomia and related diseases in the United States. These figures underscore the need for effective treatments and the importance of addressing xerostomia as a symptom of larger health concerns.
Sjogren Syndrome Foundation of America's efforts to create awareness and support patients affected by Sjogren's syndrome, a condition often accompanied by xerostomia. The foundation conducts awareness programs and aids individuals suffering from this autoimmune disorder in both the United States & Canada. Introduced "5-Year Breakthrough Goal" with the objective of reducing the time it takes to diagnose the condition to less than 2.5 years by 2017. By doing so, they aimed to expedite the diagnosis and treatment of Sjogren's syndrome, which often includes addressing the issue of xerostomia as part of the comprehensive care plan.
Additionally, major players in the market recognize the importance of both acquiring emerging companies and conducting awareness programs. For instance, Orajel initiated a campaign in collaboration with iCrossing; the goal of this campaign was to educate parents about the significance of oral care, which includes addressing issues like xerostomia. By educating the public about oral health and conditions like dry mouth, these initiatives contribute to increasing awareness about xerostomia and its treatment options.
Xerostomia Therapeutics Market Report Highlights
The OTC segment dominated the market, as they are easily available, affordable, and have a higher efficacy rate
The dentifrices segment will grow rapidly, as they are more efficient as they focus on improving the salivary stimulants by restoring essential salivary components, Calcium, and phosphate
North America held the largest share, primarily due to patient awareness regarding the ill effects of xerostomia, effective treatment options via its well-developed medical infrastructure
The key market players include GlaxoSmithKline, Hikma Pharmaceuticals, Pendopharm, Sun Pharma, Lupin Pharmaceuticals, and Pfizer
Polaris market research has segmented the xerostomia therapeutics market report based on type, product, and region:
Xerostomia Therapeutics, Type Outlook (Revenue - USD Billion, 2023 - 2032)
Xerostomia Therapeutics, Product Outlook (Revenue - USD Billion, 2023 - 2032)
- Salivary Stimulants
- Salivary Substitutes
- Dentifrices
Xerostomia Therapeutics, Regional Outlook (Revenue - USD Billion, 2023 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Xerostomia Therapeutics Market Insights
- 4.1. Xerostomia Therapeutics Market - Industry Snapshot
- 4.2. Xerostomia Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increased prevalence of oral health conditions
- 4.2.1.2. Growing demand for palliative care and supportive therapies
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Side effects of some xerostomia medications
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Xerostomia Therapeutics Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Xerostomia Therapeutics Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Xerostomia Therapeutics, by Product, 2019-2032 (USD Billion)
- 5.3. Salivary Stimulants
- 5.3.1. Global Xerostomia Therapeutics Market, by Salivary Stimulants, by Region, 2019-2032 (USD Billion)
- 5.4. Salivary Substitutes
- 5.4.1. Global Xerostomia Therapeutics Market, by Salivary Substitutes, by Region, 2019-2032 (USD Billion)
- 5.5. Dentifrices
- 5.5.1. Global Xerostomia Therapeutics Market, by Dentifrices, by Region, 2019-2032 (USD Billion)
6. Global Xerostomia Therapeutics Market, by Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 6.3. OTC
- 6.3.1. Global Xerostomia Therapeutics Market, by OTC, by Region, 2019-2032 (USD Billion)
- 6.4. Prescription
- 6.4.1. Global Xerostomia Therapeutics Market, by Prescription, by Region, 2019-2032 (USD Billion)
7. Global Xerostomia Therapeutics Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Xerostomia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 7.3. Xerostomia Therapeutics Market - North America
- 7.3.1. North America: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.3.2. North America: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.3.3. Xerostomia Therapeutics Market - U.S.
- 7.3.3.1. U.S.: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.3.3.2. U.S.: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.3.4. Xerostomia Therapeutics Market - Canada
- 7.3.4.1. Canada: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.3.4.2. Canada: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4. Xerostomia Therapeutics Market - Europe
- 7.4.1. Europe: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.2. Europe: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.3. Xerostomia Therapeutics Market - UK
- 7.4.3.1. UK: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.3.2. UK: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.4. Xerostomia Therapeutics Market - France
- 7.4.4.1. France: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.4.2. France: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.5. Xerostomia Therapeutics Market - Germany
- 7.4.5.1. Germany: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.5.2. Germany: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.6. Xerostomia Therapeutics Market - Italy
- 7.4.6.1. Italy: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.6.2. Italy: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.7. Xerostomia Therapeutics Market - Spain
- 7.4.7.1. Spain: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.7.2. Spain: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.8. Xerostomia Therapeutics Market - Netherlands
- 7.4.8.1. Netherlands: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.8.2. Netherlands: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.4.9. Xerostomia Therapeutics Market - Russia
- 7.4.9.1. Russia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.4.9.2. Russia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5. Xerostomia Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.3. Xerostomia Therapeutics Market - China
- 7.5.3.1. China: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.3.2. China: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.4. Xerostomia Therapeutics Market - India
- 7.5.4.1. India: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.4.2. India: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.5. Xerostomia Therapeutics Market - Malaysia
- 7.5.5.1. Malaysia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.5.2. Malaysia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.6. Xerostomia Therapeutics Market - Japan
- 7.5.6.1. Japan: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.6.2. Japan: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.7. Xerostomia Therapeutics Market - Indonesia
- 7.5.7.1. Indonesia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.7.2. Indonesia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.5.8. Xerostomia Therapeutics Market - South Korea
- 7.5.8.1. South Korea: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.5.8.2. South Korea: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6. Xerostomia Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.3. Xerostomia Therapeutics Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.6.3.2. Saudi Arabia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.4. Xerostomia Therapeutics Market - UAE
- 7.6.4.1. UAE: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.6.4.2. UAE: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.5. Xerostomia Therapeutics Market - Israel
- 7.6.5.1. Israel: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.6.5.2. Israel: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.6.6. Xerostomia Therapeutics Market - South Africa
- 7.6.6.1. South Africa: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.6.6.2. South Africa: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7. Xerostomia Therapeutics Market - Latin America
- 7.7.1. Latin America: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.3. Xerostomia Therapeutics Market - Mexico
- 7.7.3.1. Mexico: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.7.3.2. Mexico: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.4. Xerostomia Therapeutics Market - Brazil
- 7.7.4.1. Brazil: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.7.4.2. Brazil: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
- 7.7.5. Xerostomia Therapeutics Market - Argentina
- 7.7.5.1. Argentina: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
- 7.7.5.2. Argentina: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Acacia Pharma
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Church & Dwight Co., Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Colgate-Palmolive Company
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. GlaxoSmithKline plc
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Hikma Pharmaceuticals PLC
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Lupin Pharmaceuticals, Inc.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. OraCoat
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Parnell Pharmaceuticals, Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Pendopharm
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Pfizer, Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Sun Pharmaceuticals Industries Ltd.
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
°ü·ÃÀÚ·á